NCT05989711Phase 2Completed

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

Study sponsor: Altimmune, Inc. · ALT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-11-25Actual
Enrollment · participants212Actual
Source updated2026-05-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis Measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis). After: Measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis Measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis) Measure: Incidence of Treatment Emergent Adverse Events.

Primary completion date changed

Before: 29 Apr 2025. After: 25 Nov 2025.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 190 participants (planned). After: 212 participants (actual).

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 1 field changed

Primary completion date changed

Before: 28 Feb 2025. After: 29 Apr 2025.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview